New CE Summit Focuses on Veterinary Neurosurgery, Innovation, and Collaboration
BOZEMAN, Mont., May 30, 2025 /PRNewswire/ -- Bridger Veterinary Specialists (BVS) proudly announces the inaugural BVS Neurosurgery Summit — a premier, two-and-a-half-day event focused on advancing the field of veterinary neurosurgery. Tailored for specialists and residents within ACVIM (Neurology), ECVN, ACVS, and ECVS, the summit will provide cutting-edge education, collaboration, and hands-on experience.
The summit will take place September 19–21, 2025, at the Kimpton Armory Hotel in beautiful Bozeman, Montana. An optional hands-on dry lab will also be offered on September 22 at the BVS hospital.
This summit provides a unique opportunity for veterinary neurologists, surgeons, house officers, and students to engage in collaborative learning and professional development.
Event Highlights
Expert-Led Sessions: Attendees will gain up to 14 hours of RACE-pending Continuing Education (CE) through case-based insights, research-driven lectures, expert-led discussions, and a half-day dry lab
Specialist-Level Lectures & Roundtables: Topics include intracranial surgery, skull reconstruction, minimally invasive neurosurgical techniques, spinal biomechanics, implant decision-making, comparative neurosurgery strategies, and advances in lumbosacral surgery.
Networking Opportunities: The summit fosters collaboration among peers and thought leaders in a picturesque mountain setting conducive to learning and recharging.
Dry Lab Registration Details:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
a day ago
- Korea Herald
Wingderm® Strengthens Presence in Asia at IMCAS Asia 2025
BEIJING, June 10, 2025 /PRNewswire/ -- From June 6 to 8, 2025, IMCAS Asia was successfully held in Bangkok, Thailand. As one of the world's leading medical aesthetic events, IMCAS Asia brought together the latest developments and trends in the Asian medical aesthetic market. Wingderm® once again showcased its innovative medical aesthetic solutions. Focusing on Asia's Growing Medical Aesthetic Market The Asian market includes both mature economies, such as China, Japan, and South Korea, as well as rapidly growing Southeast Asian countries. This makes the region a crucial player in the global medical aesthetic industry. IMCAS Asia is not only a platform for sharing knowledge, but also offers Wingderm® a valuable opportunity to better understand practitioner perspectives and stay aligned with market trends, supporting product upgrades and strategic expansion. Tech Meets Trust: Driving Mutual Growth through Innovation At IMCAS Asia, Wingderm® presented a series of advanced medical aesthetic devices, including Mesoskin for non-invasive delivery, Lasermach for fast and comfortable laser hair removal, and Renuva, a device powered by 1550nm non-ablative fractional laser for skin resurfacing. Our success at the event was thanks to the support of our local distributor in Thailand. We will continue this close partnership for mutual benefit. Next Stop: TAS 2025 in Las Vegas Driven by technology and innovation, Wingderm® is always looking for new ways to apply our technologies and enhance user experiences. Through industry events, we share our latest advancements and strengthen connections with industry professionals around the world. Wingderm® will be at booth 712 during TAS 2025, held from June 27 to 29 in Las Vegas. Please visit us there！ About Wingderm® Wingderm® since its establishment in 2016, with the aim of "Aesthetics&Technology, Easy to Achieve", provides leading and reliable intelligent photoelectric medical aesthetic devices, which have been exported to more than 80 countries, with over 25,000 units installed, recognized for safety and effectiveness by experts and beauty seekers.
Korea Herald
4 days ago
- Korea Herald
HIRONIC Successfully Hosts First Asia Innovation Summit 2025
SEOUL, South Korea, June 7, 2025 /PRNewswire/ -- HIRONIC, a global leader in non-invasive medical aesthetic technology, has successfully hosted its inaugural 'HIRONIC Innovation Summit 2025. Asia Edition' in Bangkok, Thailand on June 5th. The event brought together approximately 100 medical professionals and medical distribution industry representatives from South Korea, Thailand, Vietnam, Malaysia, Indonesia, Myanmar, and other countries. Across four in-depth clinical sessions, speakers presented the latest approaches to skin rejuvenation, covering multi-layered face and body lifting, advanced scar treatment, and next-generation needle-free drug delivery technologies. One of the keynote lectures was delivered by Dr. Wonkyu Hong, Director and dermatologist at Human Dermatology Clinic and Executive Director of the Human Clinical Trial Center in South Korea. Dr. Hong explored the rapidly evolving role of needle-free technology in aesthetic medicine, sharing his clinical experience while emphasizing both its therapeutic advantages and its significant market growth potential driven by increasing patient demand for non-invasive rejuvenation solutions. Dr. Thitikom Limrattanamekha, founder and CEO of Optima Aesthetics in Thailand and an experienced laser specialist in scar treatment, skin quality improvement, and pigmentation management, shared his expertise on combining pico laser and RF microneedling to achieve highly effective outcomes in complex scarring cases. His presentation highlighted how advanced combination protocols are reshaping non-surgical treatment approaches and expanding therapeutic options for physicians worldwide. The symposium also provided a platform to showcase the clinical advancements and growing market relevance of HIRONIC's flagship export technologies, including New Doublo™, PICOHI™, and the latest needle-free delivery system Synerjet PRO™. Sasha Borovtsova, Head of Global Marketing Office at HIRONIC, stated, "This summit not only showcased the real-world clinical applications of our technologies but also underscored the accelerating global demand for safer, more versatile, and highly effective aesthetic solutions. As innovation continues to drive market growth, HIRONIC remains committed to advancing technology and strengthening global expertise and partnerships through events like the HIRONIC Innovation Summit." Headquartered in South Korea, HIRONIC is a leading global manufacturer of medical aesthetic devices, specializing in HIFU, RF, laser, and needle-free technologies. With a presence in over 80 countries, HIRONIC has introduced iconic devices such as Doublo™, Doublo Gold™, and New Doublo 2.0™ to the international market.
Korea Herald
5 days ago
- Korea Herald
HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid
JAVENÉ, France, June 6, 2025 /PRNewswire/ -- On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high patronage of the President of the French Republic, HTL Biotechnology confirms its position as a globalleader in the development and production of pharmaceutical-grade biopolymers, by inaugurating a new production unit dedicated to sterile hyaluronic acid at its Javené (Ille-et-Vilaine) site, a true flagship of French biomanufacturing. With over 30 years of expertise in biopolymers, HTL Biotechnology is reaffirming its commitment through this new production unit to the development of innovative therapeutic solutions for the medicine of today and tomorrow. The manufacture of sterile hyaluronic acid opens the way to new therapeutic opportunites . This cutting-edge process now makes it possible to combine hyaluronic acid with heat-sensitive active molecules, previously incompatible with traditional heat sterilization methods. Simultaneously, mastery of aseptic processes eliminates any risk of microbial contamination and ensures optimum pharmaceutical quality. This innovation marks a decisive step in the development of new combined formulations, bringing improved clinical benefits for patients in many fields, such as ophthalmology and drug delivery. This €12 million investment, part of HTL Biotechnology's €100 million 2022-2026 strategic plan, pursues two main goals: to explore new opportunities in bioproduction, and to strengthen the company's position as a key player in future applications of hyaluronic acid in healthcare. Production is scheduled to start in 2026, following qualification and validation of the industrial equipment. To guarantee the quality and efficiency of this new production unit, HTL Biotechnology has set up specific in-house training courses to instruct its staff in aseptic procedures and the handling of this new product. Because of the highly technical nature of this product, a team of ten specialists has been trained in the specific skills required for its production ensuring the highest quality standards. François Fournier, CEO of HTL Biotechnology, states: " I'm delighted with the prospects this investment gives us for further innovation in pharmaceutical-grade biopolymers. The breadth and complementarity of our portfolio is unique, and we are proud to be able to serve our customers even better. Thanks to this new unit, promising future applications can be explored, offering innovative solutions for the benefit of patients. I am delighted to be able to count on this new facility, which makes our historic Javené site a true flagship for French bioproduction." As an active member of France Biolead, HTL Biotechnology is proud to take part in the second National Biomanufacturing and Biomedicines Day, which this year enjoys the patronage of French President Emmanuel Macron. The company welcomes this recognition, which underscores the strategic importance of the French biomanufacturing and biomedical industry, at the heart of the challenges facing public health, and France. About HTL HTL Biotechnology is a French biotech company and world leader in the development and responsible biomanufacturing of pharmaceutical-grade biopolymers (Hyaluronic Acid, Polynucleotides and soon recombinant human collagen). These biopolymers are used by healthcare companies to develop treatments in a variety of leading therapeutic areas such as ophthalmology, dermatology, medical aesthetics and rheumatology. HTL Biotechnology recently strengthened its position as world leader in the development of pharmaceutical-grade biopolymers by acquiring, through its subsidiary HTL Biotechnology Innovation Inc. (HTL BII - New Jersey), a recombinant protein platform whose most advanced product is recombinant human collagen type III (rhCOL3) at a world-class scientific research center. To meet the world's growing need for biopolymers, the company also has subsidiaries in Asia and is building a neuromodulator production unit in the United States (HTL BMI - Massachusetts). Historically based in Javené (Brittany - France), the company brings together production, innovation, R&D , as well as quality activities on its site. HTL Biotechnology employs nearly 300 people worldwide. Press contact
